Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900)

Vance, Gail H.; Kim, Haesook; Hicks, Gary A.; Cherry, Athena M.; Higgins, Rodney R.; Hulshizer, Rachael L.; Tallman, Martin S.; Fernandez, Hugo F.; Dewald, Gordon W.

doi:10.1016/j.leukres.2006.07.026

Cited by 19 publications

(16 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7 Various probe strategies (eg, single fusion, dual fusion, or break-apart) are used depending on the technical and clinical circumstances. 8 For example, a dual fusion strategy has better analytic sensitivity for finding low level PML-RARA, while a break-apart probe strategy detects any of the relevant RARA translocations irrespective of the partner gene.…”

Section: Fluorescence In Situ Hybridizationmentioning

confidence: 99%

“…7,28,29 Another defect that is missed by karyotype involves partial tandem duplication of the MLL gene on chromosome 11q23. 30,31 Whether MLL is altered by partial tandem duplication or by translocation with any of Ͼ70 partners, MLL rearrangement portends a poor outcome in AML, except for t(9;11), which imparts an intermediate risk.…”

Section: Assays For Cryptic Translocation and Mll Gene Defectsmentioning

confidence: 99%

See 1 more Smart Citation

Genetic Tests To Evaluate Prognosis and Predict Therapeutic Response in Acute Myeloid Leukemia

Gulley

Shea

Fedoriw

2010

The Journal of Molecular Diagnostics

View full text Add to dashboard Cite

show abstract

Section: Fluorescence In Situ Hybridizationmentioning

confidence: 99%

Section: Assays For Cryptic Translocation and Mll Gene Defectsmentioning

confidence: 99%

Genetic Tests To Evaluate Prognosis and Predict Therapeutic Response in Acute Myeloid Leukemia

Gulley

Shea

Fedoriw

2010

The Journal of Molecular Diagnostics

View full text Add to dashboard Cite

show abstract

“…1 For example, aiming to improve accuracy of leukemia diagnosis, a number of prospective clinical trials were conducted in the last several years to assess the clinical utility of FISH technology. [2][3][4][5][6] These studies confirmed that FISH supplemented standard the karyotyping method by detecting abnormalities in interphase nuclei and clarifying cryptic or complex abnormalities. As a result, the current USA National Cancer Institute guidelines recommended the incorporation of interphase FISH test to the diagnostic workup of leukemia patients, in particular for all patients diagnosed and confirmed with chronic myeloid leukemia (CLL).…”

Section: Introductionmentioning

confidence: 60%

Potential clinical impact of three-dimensional visualization for fluorescent in situ hybridization image analysis

Zhang

et al. 2012

J. Biomed. Opt.

View full text Add to dashboard Cite

Abstract. Chromosomal translocation is strong indication of cancers. Fluorescent in situ hybridization (FISH) can effectively detect this translocation and achieve high accuracy in disease diagnosis and prognosis assessment. For this purpose, whole chromosome paint probes are utilized to image the configuration of DNA fragments. Although twodimensional (2-D) microscopic images are typically used in FISH signal analysis, we present a case where the translocation occurs in the depth direction where two probed FISH signals are overlapped in the projected image plane. Thus, the translocation cannot be identified. However, when imaging the whole specimen with a confocal microscope at 27 focal planes with 0.5-μm step interval, the translocation can be clearly identified due to the free rotation capability by the three-dimensional (3-D) visualization. Such a translocation detection error of using 2-D images might be critical in detecting and diagnosing early or subtle disease cases where detecting a small number of abnormal cells can make diagnostic difference. Hence, the underlying implication of this report suggests that utilizing 3-D visualization may improve the overall accuracy of FISH analysis for some clinical cases. However, the clinical efficiency and cost of using 3-D versus 2-D imaging methods are also to be assessed carefully.

show abstract

“…This statement was supported by 28 studies, § § § § § § comprising 2 meta-analyses, 408,410 one RCT, 414 ‡ ‡ ‡ ‡ ‡ ‡ ‡ None of those studies were found to have methodological flaws that would raise concerns about the studies' findings. Refer to Supplemental Table 20 for the quality-assessment results of studies included for statement 23.…”

mentioning

confidence: 93%

“…179 Fluorescence in situ hybridization studies as part of clinical trials were typically performed at a central laboratory or tertiary care center. 106,112,413,414 Molecular studies confirming mutations and gene rearrangements as part of clinical trials were typically performed at a central laboratory or tertiary care center § § § § § § § § as were DNA methylation studies. 196 If testing involves making specimens for routine or cytochemical staining or performing flow cytometry on BM at a central laboratory, the sample should be shipped overnight and processed within 24 hours of being obtained.…”

mentioning

confidence: 99%

Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology

Arber¹,

Borowitz²,

Cessna³

et al. 2017

Archives of Pathology &Amp; Laboratory Medicine

100

View full text Add to dashboard Cite

Context.-A complete diagnosis of acute leukemia requires knowledge of clinical information combined with morphologic evaluation, immunophenotyping and karyotype analysis, and often, molecular genetic testing. Although many aspects of the workup for acute leukemia are well accepted, few guidelines have addressed the different aspects of the diagnostic evaluation of samples from patients suspected to have acute leukemia.Objective.-To develop a guideline for treating physicians and pathologists involved in the diagnostic and prognostic evaluation of new acute leukemia samples, including acute lymphoblastic leukemia, acute myeloid leukemia, and acute leukemias of ambiguous lineage.Design.-The College of American Pathologists and the American Society of Hematology convened a panel of experts in hematology and hematopathology to develop recommendations. A systematic evidence review was conducted to address 6 key questions. Recommendations were derived from strength of evidence, feedback received during the public comment period, and expert panel consensus.Results.-Twenty-seven guideline statements were established, which ranged from recommendations on what clinical and laboratory information should be available as part of the diagnostic and prognostic evaluation of acute leukemia samples to what types of testing should be performed routinely, with recommendations on where such testing should be performed and how the results should be reported.Conclusions.-The guideline provides a framework for the multiple steps, including laboratory testing, in the evaluation of acute leukemia samples. Some aspects of the guideline, especially molecular genetic testing in acute leukemia, are rapidly changing with new supportive literature, which will require on-going updates for the guideline to remain relevant.

show abstract

Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900)

Cited by 19 publications

References 12 publications

Genetic Tests To Evaluate Prognosis and Predict Therapeutic Response in Acute Myeloid Leukemia

Genetic Tests To Evaluate Prognosis and Predict Therapeutic Response in Acute Myeloid Leukemia

Potential clinical impact of three-dimensional visualization for fluorescent in situ hybridization image analysis

Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology

Contact Info

Product

Resources

About